AXIM Biotechnologies, Inc.
AXIM
$0.003
$0.000.00%
| Weiss Ratings | AXIM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | AXIM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AXIM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -2.07 | |||
| Price History | AXIM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -6.25% | |||
| 30-Day Total Return | -16.67% | |||
| 60-Day Total Return | 25.00% | |||
| 90-Day Total Return | -23.08% | |||
| Year to Date Total Return | 57.89% | |||
| 1-Year Total Return | -82.86% | |||
| 2-Year Total Return | -84.62% | |||
| 3-Year Total Return | -98.12% | |||
| 5-Year Total Return | -98.72% | |||
| 52-Week High % Change | -84.21% | |||
| 52-Week Low % Change | 130.77% | |||
| Price | AXIM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.02 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Dec 11, 2024 | |||
| 52-Week High Price (Date) | Jul 23, 2024 | |||
| Valuation | AXIM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 938.69K | |||
| Enterprise Value | 7.72M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.02 | |||
| Earnings Per Share Growth | -55.04% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 10.00 | |||
| Price/Book (Q) | -0.09 | |||
| Enterprise Value/Revenue (TTM) | 82.96 | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -4.09 | |||
| Enterprise Value/EBIT | -3.33 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | AXIM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 288.91M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AXIM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 923 4422 | |||
| Address | 6191 Cornerstone Court, East San Diego, CA 92121 | |||
| Website | www.aximbiotech.com | |||
| Country | United States | |||
| Year Founded | 2010 | |||
| Profitability | AXIM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -2,490.53% | |||
| Profit Margin | -4,447.09% | |||
| Management Effectiveness | AXIM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -36.31% | |||
| Return on Equity | -- | |||
| Income Statement | AXIM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 93.00K | |||
| Total Revenue (TTM) | 93.00K | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | 91.20K | |||
| EBITDA (TTM) | -1.89M | |||
| EBIT (TTM) | -2.32M | |||
| Net Income (TTM) | -4.14M | |||
| Net Income Avl. to Common (TTM) | -4.14M | |||
| Total Revenue Growth (Q YOY) | 76.77% | |||
| Earnings Growth (Q YOY) | 39.04% | |||
| EPS Diluted (TTM) | -0.02 | |||
| EPS Diluted Growth (Q YOY) | 50.00% | |||
| Balance Sheet | AXIM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 6.00K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 20.20K | |||
| Total Preferred Equity (Q) | 0.00 | |||
| Total Equity (Q) | -9.53M | |||
| Current Ratio (Q) | 0.003 | |||
| Book Value Per Share (Q) | -$0.03 | |||
| Total Assets (Q) | 3.73M | |||
| Total Current Liabilities (Q) | 6.57M | |||
| Total Debt (Q) | 6.78M | |||
| Total Liabilities (Q) | 13.26M | |||
| Total Common Equity (Q) | -9.53M | |||
| Cash Flow | AXIM - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -2.80K | |||
| Cash from Financing (TTM) | 670.40K | |||
| Net Change in Cash (TTM) | -91.50K | |||
| Levered Free Cash Flow (TTM) | -3.02M | |||
| Cash from Operations (TTM) | -759.00K | |||
